Pascual, Tomás http://orcid.org/0000-0001-8431-3183
Fernandez-Martinez, Aranzazu http://orcid.org/0000-0002-2311-4356
Agrawal, Yash
Pfefferle, Adam D. http://orcid.org/0000-0002-4924-1767
Chic, Nuria
Brasó-Maristany, Fara
Gonzàlez-Farré, Blanca
Paré, Laia http://orcid.org/0000-0002-4904-558X
Villacampa, Guillermo
Saura, Cristina
Hernando, Cristina
Muñoz, Montserrat
Galván, Patricia
Gonzàlez-Farré, Xavier
Oliveira, Mafalda http://orcid.org/0000-0001-9152-8799
Gil-Gil, Miguel
Ciruelos, Eva
Villagrasa, Patricia
Gavilá, Joaquín
Prat, Aleix http://orcid.org/0000-0003-2377-540X
Perou, Charles M.
Article History
Received: 11 September 2023
Accepted: 22 February 2024
First Online: 6 March 2024
Competing interests
: T.P. reports having received Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) from Astra Zeneca, Consulting Fees (e.g., advisory boards) from Novartis, and Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) from Pfizer. L.P. is an employee of Reveal Genomics and has a patent (EP 20 382 679.7—in vitro method for the prognosis of patients suffering from HER2-positive breast cancer). G.V. has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from MSD, GSK, Pierre Fabre, and Pfizer and has participated on a data safety monitoring board or advisory board for AstraZeneca. C.S. has served as consultant, participated in advisory boards or received travel grants from AstraZeneca, AX’s Consulting, Byondis BV, Celgene, Daiichi Sankyo, Eisai, F. Hoffmann - La Roche Ltd, Exact Sciences, Exeter Pharma, Genomic Health, Merck, Sharp and Dhome España S.A., Novartis, Odonate Therapeutics, Pfizer, Philips Healthwork, Pierre Fabre, Pint Pharma, prIME Oncology, Puma Biotechnology, Seagen, Synthon, Sanofi Aventis and Zymeworks. M.M. declares the following competing interests: expert testimony honoraria from Novartis, Roche, and Eisai; advisory board honoraria from Pierre Fabre, and Seagen; and conference travel grants from Roche, Pfizer, Gilead and Lilly. X.G. reports honoraria and personal fees from Roche, Novartis and Gilead, Roche, honoraria, travel support, personal fees from AstraZeneca and Pierre Fabre, and personal, travel and congress support from Eli Lilly. M.O. reports financial relationships with AstraZeneca, Guardant Health, Roche, MSD, Pfizer, SeaGen, iTEOS, Eisai, Novartis, Relay Therapeutics and Gilead. E.C. reports personal fees from Roche, personal fees from Lilly, personal fees from Novartis, personal fees from Pfizer, during the conduct of the study. J.G. reports grants and personal fees from NOVARTIS, grants and personal fees from PFIZER, grants and personal fees from ROCHE, outside the submitted work. A.P. has declared personal honoraria from Pfizer, Novartis, Roche, MSD Oncology, Lilly and Daiichi Sankyo, travel, accommodations, and expenses paid by Daiichi Sankyo, research funding from Nanostring Technologies, Roche and Novartis, consulting/advisory role for Nanostring Technologies, Roche, Novartis, Pfizer, Oncolytics Biotech, Amgen, Lilly, MSD, PUMA and Daiichi Sankyo, Inc. outside the submitted work. C.M.P. is an equity stockholder and consultant of BioClassifier LLC; C.M.P. is also listed as an inventor on patent applications for the Breast PAM50 Subtyping assay. The other authors declare no financial or non-financial competing interests.